Murdock Hunter R. 4

What Happened Hunter R. Murdock, General Counsel of Axsome Therapeutics (AXSM), received a grant of 7,224 performance stock units (PSUs) on April 21, 2026. The Form 4 reports the award as a derivative grant (transaction code A) with a reported acquisition price of $0.00—this is a compensation award, not an open-market purchase.

Key Details

• Transaction date: 2026-04-21 (reported on Form 4 filed 2026-04-23).
• Grant: 7,224 PSUs; price reported as $0.00 (award/compensation).
• Derivative detail: Each PSU represents a contingent right to receive one share of common stock (Footnote F1).
• Vesting conditions: PSUs vest only upon achievement of specified sales and commercial launch milestones and continued service at each vesting date (Footnote F2).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Filing shows report period 4/21/2026 and was filed 4/23/2026 (appears timely under Form 4 rules).

Context PSUs are conditional awards tied to performance and service and do not represent immediate share ownership until vested and settled. Such grants are common as executive compensation and do not itself indicate a buy or sell decision in the market.